S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
The ONLY Way to Play Markets Like These (Ad)pixel
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
The ONLY Way to Play Markets Like These (Ad)pixel
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
The ONLY Way to Play Markets Like These (Ad)pixel
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
The ONLY Way to Play Markets Like These (Ad)pixel
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
The ONLY Way to Play Markets Like These (Ad)pixel
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
The ONLY Way to Play Markets Like These (Ad)pixel
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
The ONLY Way to Play Markets Like These (Ad)pixel
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
The ONLY Way to Play Markets Like These (Ad)pixel
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
NASDAQ:EOLS

Evolus - EOLS Stock Forecast, Price & News

$10.61
+0.55 (+5.47%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.05
$10.66
50-Day Range
$8.95
$13.72
52-Week Range
$5.06
$14.34
Volume
452,576 shs
Average Volume
742,377 shs
Market Capitalization
$595.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.33

Evolus MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
44.5% Upside
$15.33 Price Target
Short Interest
Healthy
5.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.92mentions of Evolus in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$345,280 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.12) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

447th out of 1,119 stocks

Pharmaceutical Preparations Industry

220th out of 549 stocks

EOLS stock logo

About Evolus (NASDAQ:EOLS) Stock

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Evolus Stock Performance

Shares of NASDAQ:EOLS opened at $10.61 on Friday. The company's 50 day simple moving average is $11.64 and its 200 day simple moving average is $11.12. The stock has a market capitalization of $595.17 million, a price-to-earnings ratio of -7.52 and a beta of 1.95. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.60 and a quick ratio of 2.36. Evolus has a 1 year low of $5.06 and a 1 year high of $14.34.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Barclays upgraded shares of Evolus from an "underweight" rating to an "equal weight" rating and lifted their price target for the company from $8.00 to $10.00 in a research report on Thursday, May 12th. Needham & Company LLC assumed coverage on shares of Evolus in a research report on Thursday, June 23rd. They issued a "buy" rating and a $18.00 price target for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $15.33.

Insider Activity at Evolus

In related news, major shareholder Medytox Inc. sold 26,000 shares of Evolus stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $13.28, for a total value of $345,280.00. Following the transaction, the insider now directly owns 7,437,652 shares of the company's stock, valued at $98,772,018.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.30% of the stock is currently owned by insiders.

Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Stock News Headlines

Short Interest in Evolus, Inc. (NASDAQ:EOLS) Declines By 7.4%
Analysts Set Evolus, Inc. (NASDAQ:EOLS) PT at $15.33
Recap: Evolus Q2 Earnings - Benzinga
Evolus's Earnings: A Preview - Benzinga
See More Headlines
Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Company Calendar

Last Earnings
3/23/2021
Today
8/19/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EOLS
Fax
N/A
Employees
167
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.33
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+44.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-46,810,000.00
Pretax Margin
-59.31%

Debt

Sales & Book Value

Annual Sales
$99.67 million
Book Value
$0.84 per share

Miscellaneous

Free Float
52,000,000
Market Cap
$595.22 million
Optionable
Optionable
Beta
1.95

Key Executives

  • Mr. David MoatazediMr. David Moatazedi (Age 44)
    Pres, CEO & Director
    Comp: $1.23M
  • Dr. Rui Avelar C.CFP (Age 60)
    Dip.SportMed, M.D., Chief Medical Officer and Head of R&D
    Comp: $660.08k
  • Mr. David K. Erickson
    VP of Investor Relations
  • Mr. Jeffrey J. Plumer
    Gen. Counsel
  • Mr. Kurt Knab
    VP of Sales
  • Ms. Crystal Muilenburg (Age 42)
    Chief Marketing Officer
  • Ms. Jessica Novak
    Sr. VP of HR













EOLS Stock - Frequently Asked Questions

Should I buy or sell Evolus stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EOLS shares.
View EOLS analyst ratings
or view top-rated stocks.

What is Evolus' stock price forecast for 2022?

6 Wall Street research analysts have issued 12 month price objectives for Evolus' shares. Their EOLS share price forecasts range from $10.00 to $20.00. On average, they anticipate the company's stock price to reach $15.33 in the next year. This suggests a possible upside of 44.5% from the stock's current price.
View analysts price targets for EOLS
or view top-rated stocks among Wall Street analysts.

How have EOLS shares performed in 2022?

Evolus' stock was trading at $6.51 at the start of the year. Since then, EOLS stock has increased by 63.0% and is now trading at $10.61.
View the best growth stocks for 2022 here
.

When is Evolus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our EOLS earnings forecast
.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) released its earnings results on Tuesday, March, 23rd. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.18. The business had revenue of $20.58 million for the quarter, compared to analysts' expectations of $20.60 million. Evolus had a negative trailing twelve-month return on equity of 107.14% and a negative net margin of 59.35%.
Read the conference call transcript
.

What guidance has Evolus issued on next quarter's earnings?

Evolus issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $150.00 million-$150.00 million, compared to the consensus revenue estimate of $150.26 million.

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolus own?
When did Evolus IPO?

(EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Who are Evolus' major shareholders?

Evolus' stock is owned by many different institutional and retail investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (6.48%), State Street Corp (1.56%), Millennium Management LLC (0.96%), Prudential Financial Inc. (0.67%), Essex Investment Management Co. LLC (0.65%) and Northern Trust Corp (0.56%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Lauren P Silvernail, Medytox Inc, Rui Avelar and Vikram Malik.
View institutional ownership trends
.

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $10.61.

How much money does Evolus make?

Evolus (NASDAQ:EOLS) has a market capitalization of $595.17 million and generates $99.67 million in revenue each year. The company earns $-46,810,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis.

How many employees does Evolus have?

The company employs 167 workers across the globe.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for the company is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at ir@evolus.com.

This page (NASDAQ:EOLS) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.